Tasly Biopharma pitches long-awaited IPO — will it trigger another $1B gold rush on HKEX?
In the run up to the Hong Kong stock exchange’s anticipated rule change — opening the door for Chinese pre-revenue biotechs to go public closer to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
